Taken together, these data indicate that shIDO treatment alone primes the TME for treatment with ICB, and data from human lung adenocarcinoma showing that high expression of CD11c and MHCII correlate significantly with longer overall survival support the hypothesis that increased antigen presentation by unconventional or professional APCs can facilitate tumor immune surveillance and would increase the efficacy of ICB treatment. The gene discussed is ITGAX; the disease is lung adenocarcinoma.